Cue Biopharma, Inc. (CUE) announced it will implement a 1-for-30 reverse stock split of its common shares, effective April 23, 2026. The move, approved at the company's Annual Meeting earlier this month, was authorized by the Board to increase the per-share market price and regain compliance with the Nasdaq's minimum bid requirement.
At the effective time, every 30 shares of issued and outstanding common stock will be automatically combined into one share, reducing the total from about 97.7 million to 3.3 million. The split does not affect the number of authorized shares or the par value of the stock.
Cue Biopharma confirmed that all outstanding options and warrants will be proportionately adjusted, and fractional shares will be settled in cash. The company's stock will begin trading on a split-adjusted basis on April 24, 2026, under the existing ticker CUE with the new CUSIP number 22978P205.
CUE has traded between $0.16 and $1.03 over the past year. The stock is currently trading at $0.53, down 20%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.